Effects of Oral Lycopene Supplementation on Vascular Function in Patients with Cardiovascular Disease and Healthy Volunteers: A Randomised Controlled Trial

The mechanisms by which a 'Mediterranean diet' reduces cardiovascular disease (CVD) burden remain poorly understood. Lycopene is a potent antioxidant found in such diets with evidence suggesting beneficial effects. We wished to investigate the effects of lycopene on the vasculature in CVD...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one Jg. 9; H. 6; S. e99070
Hauptverfasser:	Gajendragadkar, Parag R., Hubsch, Annette, Mäki-Petäjä, Kaisa M., Serg, Martin, Wilkinson, Ian B., Cheriyan, Joseph
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States Public Library of Science 09.06.2014 Public Library of Science (PLoS)
Schlagworte:	Acetylcholine Administration, Oral Adult Aged Aged, 80 and over Antioxidants Antioxidants (Nutrients) Antioxidants - administration & dosage Antioxidants - therapeutic use Arginine Atherosclerosis Bioavailability Biology and Life Sciences Blood pressure Blood Pressure - drug effects Cardiac patients Cardiovascular disease Cardiovascular diseases Cardiovascular Diseases - blood Cardiovascular Diseases - drug therapy Cardiovascular Diseases - physiopathology Care and treatment Carotenoids - administration & dosage Carotenoids - therapeutic use Cholesterol Clinical trials Diabetes Diet Dietary supplements Dietary Supplements - analysis Disease control Disease prevention Double-Blind Method Endothelium Exercise Female Forearm Health services Hospitals Humans Hypertension Lipids Lipoproteins (low density) Low density lipoprotein Low density lipoproteins Lycopene Male Medicine and Health Sciences Mediterranean diet Middle Aged Monomethyl-L-arginine Nitric oxide Nitroprusside Oxidative stress Patients Pharmacology Physiology Plethysmography Randomization Regional Blood Flow - drug effects Signal transduction Sodium Sodium nitroprusside Statins Stiffness Studies Supplementation Vascular Stiffness - drug effects Vasodilation
ISSN:	1932-6203, 1932-6203
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The mechanisms by which a 'Mediterranean diet' reduces cardiovascular disease (CVD) burden remain poorly understood. Lycopene is a potent antioxidant found in such diets with evidence suggesting beneficial effects. We wished to investigate the effects of lycopene on the vasculature in CVD patients and separately, in healthy volunteers (HV). We randomised 36 statin treated CVD patients and 36 healthy volunteers in a 2∶1 treatment allocation ratio to either 7 mg lycopene or placebo daily for 2 months in a double-blind trial. Forearm responses to intra-arterial infusions of acetylcholine (endothelium-dependent vasodilatation; EDV), sodium nitroprusside (endothelium-independent vasodilatation; EIDV), and NG-monomethyl-L-arginine (basal nitric oxide (NO) synthase activity) were measured using venous plethysmography. A range of vascular and biochemical secondary endpoints were also explored. EDV in CVD patients post-lycopene improved by 53% (95% CI: +9% to +93%, P = 0.03 vs. placebo) without changes to EIDV, or basal NO responses. HVs did not show changes in EDV after lycopene treatment. Blood pressure, arterial stiffness, lipids and hsCRP levels were unchanged for lycopene vs. placebo treatment groups in the CVD arm as well as the HV arm. At baseline, CVD patients had impaired EDV compared with HV (30% lower; 95% CI: -45% to -10%, P = 0.008), despite lower LDL cholesterol (1.2 mmol/L lower, 95% CI: -1.6 to -0.9 mmol/L, P<0.001). Post-therapy EDV responses for lycopene-treated CVD patients were similar to HVs at baseline (2% lower, 95% CI: -30% to +30%, P = 0.85), also suggesting lycopene improved endothelial function. Lycopene supplementation improves endothelial function in CVD patients on optimal secondary prevention, but not in HVs. ClinicalTrials.gov NCT01100385.
Bibliographie:	ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 Conceived and designed the experiments: JC IBW. Performed the experiments: PRG AH KMM MS IBW JC. Analyzed the data: PRG AH MS KMM JC. Contributed reagents/materials/analysis tools: PRG AH KMM MS IBW JC. Wrote the paper: PRG AH KMM MS IBW JC. Competing Interests: The authors declare the following: Cambridge Theranostics donated drugs and placebo to the study. Ateronon, a food supplement, is a registered trademark of CamNutra. The authors acknowledge unrestricted educational donations made by Cambridge Theranostics and CamNutra to Addenbrooke’s Charitable Trust. The donations were unrelated to the trial, which was not funded by either company. The commercial companies had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.
ISSN:	1932-6203 1932-6203
DOI:	10.1371/journal.pone.0099070